ArchiveOrganoid is to cultivate tissue-derived adult stem cells into a self-organizing structures through three-dimensional (3D) culture technology, which are derived from pluripotent stem cells or progenitor cells of isolated organs. So far, many organoids have been successfully cultured from mouse and human stem cells. Under the 3D culture system, tumor organoids can be expanded, cryopreserved and genetically modified for a long time, and maintain genetic and phenotypic stability can be maintained in the process of expansion and cryopreservation, which has been widely used in the research of various tumors. This article reviews the development and research progress of tumor organoids.
With the rapid development of immunology and immunotherapy, it is increasingly possible and important to understand the interaction and mechanism between immune cells and tumor cells in order to improve the clinical effect of immunotherapy and develop new treatment methods. Traditional two-dimensional cell culture has various limitations, and the new organoids summarize the complex environment of the original tissue, and are highly similar to the original tissue or organ in vivo in terms of genome and molecular markers. The co-culture system of organoids and immune cells creates an immune environment which mimics the tumor microenvironment in vivo and provides an ideal experimental platform for autoimmune diseases, tumor immune research and immunotherapy. This article reviewed the progress of the co-culture system of tumor organoids and immune cells and the mechanism of their interaction.
As a new in vitro basic research model in recent years, organoids have complex structures and cell types similar to real organs, and can simulate the physiological function of primitive tissues or organs. As a special organ in human body, pancreas contains internal and external secretory glands. Although pancreatic ducts and islet like organs derived from adult tissues and pluripotent stem cells have been expanded in vitro for a long time, the development of pancreatic organoid technology still faces many challenges, and the establishment of complex pancreatic organoids closer to the real situation of human body is still a research difficulty that needs to be solved urgently. This paper reviewed the development of pancreas, the construction methods of existing pancreatic organoid models and their related applications.
As one of the branches of genetics, epigenetics can affect the occurrence and progression of tumors through DNA methylation, chromatin remodeling, histone modification, non-coding RNA regulation, genomic imprinting, gene silencing, RNA editing and other mechanisms. The research and development of new drugs targeting epigenetics has become one of the hotspots of anti-cancer drugs. This article reviews the clinical research progress of epigenetic anti-cancer drugs in different therapeutic fields, combination therapy and researches in drug resistance, to provide an evidence for the follow-up research and clinical usage of these drugs.
Mesenchymal-epithelial transition factor (MET) is an important tumor driver gene in non-small cell lung cancer (NSCLC). In recent years, targeted therapy for MET signaling pathway has become a new target for lung cancer treatment. As the world's first oral, highly selective and potent MET inhibitor, tepotinib has been approved by Japan and the United States FDA for the treatment of advanced or recurrent NSCLC patients with unresectable and MET exon 14 skipping mutations. At the same time, it has shown good safety and efficacy in clinical studies. This article mainly reviewed the current clinical studies of tepotinib in NSCLC, liver cancer, NSCLC with brain metastasis and so on.
To investigate the effects of dihydromyricetin (DMY) on the proliferation, apoptosis of human lens epithelial cells SRA01/04 and its possible molecular mechanism.
SRA01/04 cells were divided into normal control (NC) group, DMY group, anti-miR-NC group, anti-miR-199b-5p group, miR-NC group, miR-199b-5p group, and DMY+miR-NC group and DMY+miR-199b-5p group. The expression level of miR-199b-5p was detected by quantitative reverse transcriptase-mediated polymerase chain reaction (qRT-PCR). Cell proliferation and apoptosis were detected by MTT assay and flow cytometry.
DMY could inhibit the proliferation and induce apoptosis of SRA01/04 cells (P<0.05) and promote the expression of miR-199b-5p in SRA01/04 cells (P<0.05). Overexpressing miR-199b-5p could inhibit the proliferation and induce apoptosis of SRA01/04 cells (P<0.05). Inhibiting miR-199b-5p could promote the proliferation and inhibit apoptosis of SRA01/04 cells (P<0.05) and could reverse the proliferation inhibition and apoptosis promotion effects of DMY on SRA01/04 cells (P<0.05).
DMY can inhibit the proliferation and induce apoptosis of human lens epithelial cells SRA01/04, and the mechanism is related to the up-regulation of miR-199b-5p expression.
To evaluate the therapeutic effect of batroxobin on rats with tinnitus and investigate its effect on neurotransmitters in inferior colliculus.
The tinnitus model was established by intraperitoneal injection of sodium salicylate combined with ''drinking water suppression''. The model rats were randomly divided into model group, positive control carbamazepine (5 mg/kg) and batroxobin (1 BU/kg) groups. Normal rats were arranged as the control group. After 15 days of intraperitoneal injection, the recovery time of drinking water suppression in each group was documented. The threshold value of auditory brainstem response (ABR) at different sound frequencies (4~28 kHz) in each rat was measured. The levels of γ-aminobutyric acid (GABA), 5-hydroxytrptamine (5-HT) and acetylcholine (ACh) in inferior colliculus in rats were detected by enzyme-linked immunosorbent assay (ELISA) and liquid chromatography/mass spectrometry (LC/MS), respectively.
Compared with the model group, the recovery time of drinking water suppression in batroxobin group was significantly longer (P<0.01). Compared with the model group, the threshold value of ABR at different sound frequencies in batroxobin group were significantly reduced (P<0.05 or P<0.01). Compared with the model group, the GABA and ACh levels in inferior colliculus in batroxobin group were markedly increased (P<0.05 or P<0.01), while the 5-HT level was markedly decreased (P<0.01).
Batroxobin could relieve tinnitus symptoms induced by sodium salicylate in rats, which may be related to the regulation of central neural plasticity and recovery of the balance of excitatory/inhibitory neurotransmitters.
To investigate the effect of canagliflozin on connective tissue growth factor (CTGF) and monocyte chemotactic protein-1 (MCP-1) in diabetic nephropathy (DN) mice and its molecular mechanism.
Thirty C57BL/6 mice were randomly divided into normal control (NC, n=10) group and model group (n=20), streptozotocin (STZ) was used to construct DN model, after successful modeling, the mice were randomly divided into DN group and DN+canagliflozin (DN+C) group. The DN+C group was treated with canagliflozin by gavage, the DN and NC groups were given matching normal saline for 8 weeks. After 8 weeks, fasting blood glucose (FBG), 24 h urine protein (UP), blood urea nitrogen (BUN) and serum creatinine (Scr) were detected, and the morphological changes of kidney tissue were observed. The mRNA and protein expressions of CTGF and MCP-1 were determined by quantitative reverse transcriptase-mediated polymerase chain reaction (qRT-PCR) and western blot, respectively.
The levels of FBG, 24 h UP, BUN and Scr in model group were significantly increased (P<0.05). Compared with NC group, the levels of FBG, 24 h UP, BUN in DN+C group were significantly decreased (P<0.05). The glomerular and tubular basement membranes in DN group were thickened, and the extracellular matrix of the glomerulus was infiltrated by inflammatory cells. The pathological changes in DN+C group were less than those in DN group. Compared with NC group, the mRNA and protein expression of CTGF and MCP-1 in DN group were significantly increased (P<0.05); compared with DN group, the mRNA and protein expression of CTGF and MCP-1 in DN+C group were significantly decreased (P<0.05).
Canagliflozin can improve the high glucose state of DN mice, protect renal function, and delay the progression of DN. The mechanism may be related to the reduction of CTGF and MCP-1 expression.
To investigate the efficacy of tenofovir alafenamide combined with mycophenolate mofetil in the treatment of hepatitis B-related immunoglobulin (Ig) A nephropathy.
A total of 82 patients with hepatitis B-related IgA nephropathy admitted to our hospital from February 2016 to February 2020 were included for retrospective analysis of their medical records, and 41 patients treated with tenofovir alafenamide were set as controls group, 41 patients treated with tenofovir alafenamide combined with mycophenolate mofetil were set as the study group. The clinical efficacy between the two groups were compared. The liver and kidney function and serum marker levels of hepatitis B virus (HBV) in the two groups before and after treatment were compared.
The total effective rate in the study group was 95.12%, which was significantly higher than 78.05% in the control group (P<0.05). After treatment, the 24-hour urinary protein quantification (24-UCFP) and alanine aminotransferase (ALT) in the two groups were significantly lower than those before treatment (P<0.05), and albumin (Alb) was significantly higher than that before treatment (P<0.05). After treatment, 24-UCFP and ALT in the study group were significantly lower than those in the control group (P<0.05), and Alb was significantly higher than that in the control group (P<0.05). After treatment, the negative rate of HBV-DNA positive in the study group was significantly higher than that in the control group (P<0.05).
Tenofovir alafenamide combined with mycophenolate mofetil in the treatment of hepatitis B-related IgA nephropathy has a definite clinical effect, and has high application value for the improvement of liver and kidney function and the control of HBV.
To investigate the impact of Shenqi Gankang tablets on clinical efficacy and immune function in the treatment of chronic hepatitis B (CHB).
A total of 182 patients with CHB from Department of Infectious Diseases, the First Affiliated Hospital of Xinxiang Medical University between January 2017 to December 2019 were collected. All patients were randomly divided into control group (n=91) and observation group (n=91). The control group was given entecavir maleate tablets, 0.5 mg/time, one time/d and the observation group was additional given Shenqi Gankang tablets, 2.1 g/time, 3 times/d on the basis of the control group. Two groups were treated for 6 months. The differences of clinical efficacy, liver function index (AST、ALT), liver fibrosis index (LN、HA、PCⅢ, Ⅳ-C), T lymphocyte subsets index (CD4+, CD8+, CD4+/CD8+), cytokine levels index (IFN-γ, IL-2, IL-4, IL-10) and incidence of adverse reactions between two groups were compared after treatment.
The total effective rates in the observation group was significantly higher than control group (P=0.014). After treatment, the ALT, AST, LN, HA, PCⅢ, Ⅳ-C, CD8+ cells, IL-4, IL-10 of two groups were significantly reduced, while CD4+ cells, CD4+/CD8+ ratio value, IFN-γ, IL-2 were significantly increased, with statistically significant differences between two groups before and after treatment (P<0.05). After treatment, the ALT, AST, LN, HA, PCⅢ, Ⅳ-C, CD8+ cells, IL-4, IL-10 of the observation group were significantly lower than that of the control group, while CD4+ cells, CD4+/CD8+ ratio value, IFN-γ, IL-2 were higher than that of the control group, with statistically significant differences (P<0.05). The incidence of adverse reactions in control and observation group was 13.19% and 12.08%, respectively. There was no significant difference between the two groups (P=0.823).
Shenqi Gankang tablet is safe and effective in the treatment of CHB, and it could significantly improve liver function and alleviate the degree of liver fibrosis. Shenqi Gankang tablet can also promote Th1 cell immune response and enhance immune function.
To observe the effects of Yiqi Yangyin recipe on serum bilirubin metabolism and insulin resistance (IR) in patients with type 2 diabetes mellitus (T2DM) combined with atherosclerosis (AS).
A total of 64 T2DM patients combined with AS admitted to the outpatient and inpatient Department of Endocrinology, Shanghai University of Traditional Chinese and Western Medicine, Shanghai Traditional Chinese Medicine (TCM)-Integrated Hospital from October 2018 to September 2019 were selected and randomly divided into observation group and control group, with 32 cases in each group. The control group was treated with routine treatment, and the observation group was treated with Yiqi Yangyin recipe on the basis of routine treatment. The course of treatment was 8 weeks. The total curative effect of TCM clinical syndromes, serum bilirubin level, homeostasis model assessment of insulin resistance (HOMA-IR) and fasting insulin (FINS) were observed.
After treatment, the levels of serum total bilirubin and serum conjugated bilirubin in the observation group were higher than those before treatment and the differences were statistically significant (P<0.001), and the improvement in the observation group was better than that in the control group, the difference was statistically significant (P<0.001). There was singnificant difference in the total curative effect of TCM clinical syndromes between the two groups (P<0.05). HOMA-IR and FINS in the observation group were significantly lower than those before treatment (P<0.001), and difference between the two groups was statistically significant (P<0.001).
Yiqi Yangyin recipe can significantly improve the metabolism of serum bilirubin and FINS and IR levels in patients with T2DM combined with AS, reflecting the basic pathogenesis of "consumptive thirst" and "deficiency of both Qi and Yin" in Yiqi Yangyin recipe, and embodying the principle of "treating diseases must be based on the principle" and providing a research direction for the prevention and treatment of T2DM combined with AS with TCM.
To investigate the association between triglyceride-glucose (TyG) index and left ventricular hypertrophy (LVH) and albuminuria in patients with hypertension.
The study participants were recruited from a residential area in the suburb of one district in Shanghai. General information and diseases history of patients with hypertension were collected by questionnaire survey. Brachial artery blood pressure was measured by Omron monitor (HEM-7124). Fasting blood was collected for biochemical including triglyceride and fasting blood glucose. Urinary protein and LVH determined by electrocardiogram Cornell product were used as indicators of target organ damage in hypertensive.
The mean age of 5 190 subjects had was (66.41±7.77) years, including 2 423 (46.7%) men, and the mean TyG index was (8.67±0.57). The TyG index of men was lower than that of women [(8.64±0.58) vs (8.69±0.55), P=0.001]. The patients were grouped by the quartile of TyG index (<8.27, 8.27≤TyG index<8.62, 8.62≤TyG index<8.98, ≥8.98), the prevalence of LVH were 4.1%, 3.4%, 4.5% and 6.2%, trend P=0.005, and the prevalence of albuminuria were 1.9%, 2.1%, 2.3% and 3.0%, trend P=0.041, respectively. Multivariate logistic regression analysis showed that the hypertensive patients in the highest quartile group had a 138% increased risk of developing LVH compared with those with the lowest quartile of TyG index group after adjustment for associated risk factors (odds ratio=2.38, 95% confidence interval: 1.45 - 6.83, P<0.001), but there was no significant association between the prevalence of albuminuria and TyG index (P≥0.22).
TyG index was associated with LVH and albuminuria, and was an influence factor for LVH in hypertension.
To analyze the related factors of proteinuria in patients with primary aldosteronism (PA), and to explore the pathogenic factors and possible mechanism of renal damage caused by PA.
Patients hospitalized in the department of hypertension, Northern Area of Ruijin Hospital and screened as suspected PA were selected from January 2013 to December 2019. The patients were divided into PA group (post salt aldosterone>100 pg/ml) and essential hypertension (EHT) group (post salt aldosterone<60 pg/ml). The baseline characteristic, blood biochemistry, related hormones and 24-hour urinary protein were collected. Proteinuria was defined as 24-hour urinary protein quantity>150 mg.
A total of 374 patients were selected, including 142 patients in PA group, accounting for 37.98%. The detection rates of proteinuria and the urine protein quantity in PA group were higher than those in EHT group (P<0.05). Logistic regression analysis was used to correct the relevant risk factors. The risk of proteinuria in PA group was 2.23 times higher than that in EHT group (P=0.016). Furthermore, multiple linear regression was used to analyze the influencing factors of urinary proteinin PA patients. For every 1 pg/dl increase of autonomic aldosterone secretion, urinary proteinin increased by 1.32 mg/24 hours. Autonomously secreted aldosterone, blood glucose, course of disease and male are the risk factors of urinary protein.
The incidence of proteinuria was higher in PA patients than in EHT patients. Autonomously secreted aldosterone, blood glucose, course of disease and male are the influencing factors of proteinuria in PA patients, especially autonomously secreted aldosterone may be a variable and specific pathogenic factor of renal damage caused by PA.
To explore the clinical efficacy of two groups of different methotrexate (MTX) treatment schemes patients with ectopic pregnancy, and provide theoretical basis for clinical treatment.
A total of 548 patients with ectopic pregnancy treated with MTX in our hospital from June 30, 2018 to June 30, 2021 were selected as the research objects. According to different MTX treatment schemes, they were divided into group A (single-dose regimen group, n=495) and group B (two-dose regimen group, n=53). The clinical data characteristics and treatment effects of the two groups were compared and analyzed.
The median of hospitalization time in group A was 10.00 (7.50, 14.50) days, and that was 16.75 (13.87, 20.00) days in group B, and there was significant difference in the average hospitalization time between the two groups (Z=-5.774, P<0.001). The median hospitalization cost in group A was 3945.00 (2880.30, 5166.50) yuan, and that was 4889.60 (4106.30,6697.68) in group B, and there was a statistical difference in the overall distribution of hospitalization cost between the two groups (Z=-3.714, P<0.001). The median time of serum β-HCG turning negative was 20.00 (14.00, 26.00) days in group A and 23.50 (18.00, 30.00) days in group B, and there was a statistical difference in the time distribution of serum β-HCG turning negative between the two groups (Z=-2.816, P=0.005). There were no significant differences between the two groups in the success rate of treatment, the rate of repeated single administration, the disappearance time of mass and the incidence of adverse reactions (P>0.05).
Both MTX treatment regimens are safe and effective in the conservative treatment of ectopic pregnancy. The single dose regimen more cost-effective in terms of hospitalization time and hospitalization expenses.
To evaluate the comparative efficacy and economic value of polysaccharide iron complex (PIC) and other oral iron supplements (ferrous sulfate, ferrous succinate, iron dextran) in treating iron deficiency anemia (IDA) patients.
Published clinical studies of PIC and other oral iron supplements in the treatment of chronic kidney disease (CKD) complicated with IDA, IDA patients during pregnancy, and children with IDA were systematically searched. Meta-analysis was performed to analyze the clinical efficacy. A decision tree model was constructed to perform cost analysis.
A total of 169 studies were identified, and 22 studies were finally included. For CKD patients with IDA, PIC had higher effective rate (94% vs 87% vs 85%) and lower adverse event (AE) rate (19% vs 84% vs 88%) compared to ferrous sulfate and ferrous succinate. The average total treatment cost per patient was decreased by ¥535 (14%) and ¥1 839 (36%) respectively in a 12-month treatment course. For pregnant IDA patients, PIC had higher effective rate (95% vs 77% vs 80% vs 77%) and lower AE rate (6% vs 38% vs 9% vs 21%) compared to ferrous sulfate, ferrous succinate and iron dextran. The average total treatment cost was decreased by ¥270 (17%), ¥654 (33%) and 3 024 (70%) respectively in a 5-month treatment course. For children with IDA, PIC had higher effective rate (91% vs 84%) and lower AE rate (8% vs 51%) compared to ferrous sulfate and exhibited a cost saving of ¥119 (14%) in a 3-month treatment course. Results of sensitivity analysis supported the robustness of the findings.
For all three types of IDA populations, PIC demonstrated better clinical efficacy and produced cost savings in comparison to other oral iron supplements.
To comprehensively analyze and evaluate the multi-dimensional value of acetyl-levo-carnitine, epalrestat and mecobalamin in the treatment of diabetic peripheral neuropathy (DPN), to provide a basis for clinical rational drug use.
The efficacy, safety, cost-effectiveness and innovation of acetyl-levo-carnitine, epalrestat and mecobalamin were comprehensively compared by literature review.
In terms of efficacy, acetyl-levo-carnitine was significantly better than mecobalamin in the median sensory nerve conduction velocity, and it was better than that of mecobalamin in the improvement of pain symptoms. Other efficacy indicators of acetyl-levo-carnitine were similar to mecobalamin and epalrestat. In terms of safety, the incidence of adverse reactions or serious adverse events of acetyl-levo-carnitine, epalrestat and mecobalamin was similar, and all of them were mild adverse reactions. In terms of cost-effectiveness, acetyl-levo-carnitine is more cost-effective than epalrestat and mecobalamin. In terms of innovation, acetyl-levo-carnitine has the dual effects of improving cellular energy metabolism and analgesia in nerve cells.
acetyl-levo-carnitine, epalrestat and mecobalamin have little difference in efficacy and safety. In terms of economy and innovation, acetyl-levo-carnitine has higher value.
Diabetic kidney disease (DKD) is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD), and CKD is closely related to dyslipidemia and ectopic lipid deposition (ELD). Previous studies have shown that hyperlipidemia can lead to the occurrence and progression of CKD, as well as DKD. Lipid regulating drugs can improve the renal prognosis of patients with type 2 diabetes mellitus (T2DM). Hyperglycemia, hypertriglyceridemia and low high density lipoprotein-cholesterol may play important roles in the development of DKD. Therefore, the relationship between abnormal lipid metabolism and DKD was discussed, and the potential mechanism of DKD lipid induced renal damage was analyzed to provide some reference for clinical diagnosis and treatment.
Sjögren syndrome (SS) is a chronic autoimmune disease characterized by destruction of exocrine glandular epithelium and severe drying of mucosal surface, with complex etiology. It is difficult to diagnose SS accurately because of its extensive manifestations and overlapping of signs and symptoms with other autoimmune diseases. At present, substitution and symptomatic treatment are mainly used in clinic to delay the disease and improve symptoms, but the effect is often not ideal, and there is no radical cure. In recent years, with the continuous development of various targeted drugs, some new theatments and means have emerged in the clinical treatment of SS. This article reviewed the therapeutic drugs of SS in recent years in order to provide reference for clinical medication.
Corona virus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are spreading globally on a large scale, threatening the safety of human life seriously, and the world needs effective drugs against COVID-19 urgently. Recently, four oral small molecule drugs have been successfully approved for market to treat patients with early mild COVID-19, they were 3C-like protease (3CLpro) inhibitor, RNA-dependent RNA polymerase (RdRp) inhibitor, monoclonal antibody, androgen receptor inhibitor. This paper briefly summarizes these four types of drugs and reviews their clinical therapeutic effects, characteristics and mechanism of action, to provide some references for the development and usage of drugs for the treatment of COVID-19.
With the development of drug clinical trials, investigator-initiated trial (IIT) plays an increasingly important role. This paper analyzed the management modes of drug clinical trial and IIT, and compared the differences of management modes between drug clinical trial and IIT, in order to provide reference for the construction of IIT management system in China.
Prostaglandin E2 has the function of dilating blood vessels and soothing smooth muscles, and has been found to play an important role in the repair of gastrointestinal mucosal wounds. Cyclooxygenase is the main synthetase of prostaglandin (PG)E2, and prostaglandin transporter and 15-hydroxyprostaglandin dehydrogenase are the main metabolic proteins. In this paper, the role of PGE2, cyclooxygenase, prostaglandin transporter and 15-hydroxyprostaglandin dehydrogenase in wound repair were reviewed to explore the characteristics of wound repair with PGE2 as the core, so as to provide some ideas and means for selecting better drug targets to promote wound repair in the future.